Delving into the Latest Updates on BN021208H with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

BN021208H

Target-

Action-

Mechanism-

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

EpilepsyEpilepsies, Partial

Inactive Indication-

Originator Organization

Shandong Bestcomm Pharmaceutical Co., Ltd.

Active Organization

Shandong Bestcomm Pharmaceutical Co., Ltd.

Shandong Langnuo Pharmaceutical Co. Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

1.主要目的：比较BN021208H和布立西坦片在健康试验参与者中空腹条件下的单次和多次给药药代动力学特征以及人体相对生物利用度。评价进食对口服BN021208H的药代动力学影响。次要目的：观察BN021208H和布立西坦片在健康人体中的安全性。评价BN021208H在健康成年试验参与者中口服给药的口感。

[Translation]

1. Primary Objective: To compare the single-dose and multiple-dose pharmacokinetic characteristics and relative bioavailability of BN021208H and briracetam tablets in healthy trial participants under fasting conditions. To evaluate the effect of food intake on the pharmacokinetics of orally administered BN021208H. Secondary Objective: To observe the safety of BN021208H and briracetam tablets in healthy individuals. To evaluate the taste of orally administered BN021208H in healthy adult trial participants.

Start Date15 Apr 2026

Sponsor / Collaborator

Shandong Bestcomm Pharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with BN021208H

Login to view more data

100 Translational Medicine associated with BN021208H

Login to view more data

100 Patents (Medical) associated with BN021208H

Login to view more data

100 Deals associated with BN021208H

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Epilepsy	Phase 1	China	Shandong Langnuo Pharmaceutical Co. Ltd.	15 Apr 2026
Epilepsies, Partial	IND Approval	China	Shandong Bestcomm Pharmaceutical Co., Ltd.	27 Feb 2025